Drug Profile
Research programme: antibody-based cancer immunotherapeutics - For-Robin
Alternative Names: hJAA-F11; JAA-F-11:DM1; JAA-F11; JAA-F11 antibodyLatest Information Update: 16 May 2023
Price :
$50
*
At a glance
- Originator University of Buffalo
- Developer For-Robin
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Breast cancer; Lung cancer
Highest Development Phases
- Preclinical Lung cancer; Triple negative breast cancer
Most Recent Events
- 16 May 2023 Preclinical development in Triple negative breast cancer and Lung cancer is ongoing in USA (For-Robin pipeline May 2023)
- 16 May 2023 Preclinical trials in Lung cancer (Diagnosis) in USA (Parenteral) (For-Robin pipeline May 2023)
- 16 May 2023 For-Robin plans first-in-human phase I trials for Breast cancer and Lung cancer in USA (Parenteral) by fall of 2023 (For-Robin pipeline May 2023)